About Us
Step Pharma is pioneering a novel class of oral drugs that specifically inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1).
Watch the leadership team discuss our lead CTPS1 inhibitor STP938
Leadership Team
Step Pharma is led by a highly motivated management team and an exceptional syndicate of international investors, all driven to bring about a step change in cancer treatment for patients.
We are a group of like-minded, experienced executives, biotechnology entrepreneurs and drug developers who have come together to bring dencatistat to the clinic as fast as possible, drawing on our prior experience of developing and commercialising life-saving treatments.
Our vision is to redefine how cancer is treated and bring our targeted therapy to patients as soon as possible.
Step Pharma’s management team has more than 50 years of collective experience in successfully developing and commercialising breakthrough cancer treatments. We bring together a range of drug discovery and development, regulatory, clinical and operational expertise in biotech and pharma.
Andrew Parker
Andrew Parker
Duc Tran
Duc Tran
Nicolas Marsault
Nicolas Marsault
Philip Beer
Philip Beer
Dr Karen Smith
Dr Karen Smith
Maureen Higgins
Maureen Higgins
Erik Van Den Berg
Erik Van Den Berg
Claus Andersson, PhD
Claus Andersson, PhD
Thibaut Roulon
Thibaut Roulon
Walter Stockinger
Walter Stockinger
Ohad Hammer
Ohad Hammer
Rémi Droller
Rémi Droller
Ward Capoen
Ward Capoen
Founding Scientist
Prof. Alain Fischer
Alain Fischer is an internationally recognized expert in the genetics of immunological disorders, primarily immunodeficiency diseases, and the development of the lymphoid system.
In 2000 he was the first to obtain clinical success with gene therapy for the treatment of children affected by SCID disease (“bubble babies”) for which he was awarded the Louis Jeantet Prize for Medicine (2001), the INSERM “Grand Prix” (2008) and the Japan Prize in 2015. He is the author of more than 600 publications and until 2016 was the Head of the Imagine Institute where he still contributes actively to fundamental and clinical research.
+
Heritage
2014
CTPS1 mutations genetically characterised by Prof. Alain Fischer and Dr. Sylvain Latour at the Imagine Institute in Paris, France
2014
2014
Step Pharma founded in Paris, France, by VC Kurma Partners, in collaboration with Sygnature Discovery
June 2014
2017
14.5 million raised from existing and new investors (Bpifrance and Pontifa)
21 November 2017
2019
Andrew Parker appointed CEO
6 September 2019
2020
Company headquarters relocation to Region Auvergne Rhônes Alpes
2020
2021
Awarded ‘First-in-class therapeutic innovation’ during the 6th MEET2WIN Oncology Convention
11 May 2021
2021
Series B financing of EUR35 million raised, includes new investors Hadean Ventures and Sunstone Life Science Ventures
24 March 2021
2022
STP938 receives CTA/IND approval and enters clinical development in lymphoma
June/July 2022
2023
Loss of CTPS2 in solid tumours is identified as a synthetic lethal effect conferring sensitivity to CTPS1 inhibition
2024
STP938 named dencatistat; receives IND approval and enters clinical development for solid tumours with an initial focus on ovarian cancer
2025
Dencatistat enters clinical development for essential thrombocythaemia
2026
Dencatistat enters Phase 2 for essential thrombocythaemia
Investors
Step Pharma is backed by a strong syndicate of leading international investors with a track record for success, turning breakthrough science into transformative approved medicines.
Partners
We welcome the opportunity to collaborate with others to bring our transformative targeted cancer treatment to market, as well as explore other applications for CTPS1 inhibition.
CTPS1
Learn more about our lead CTPS1 Inhibitor.
Therapeutic Areas
Learn more about our therapeutic areas.
Patients
Learn more about our research and clinical trials.
Contact
Get in touch with us.
Step Pharma
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex
01630 Saint-Genis-Pouilly
France
